United States: WilmerHale Advises Intercept Pharmaceuticals In $460M Public Offering
Last Updated: July 21 2016

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023. Intercept used a portion of the proceeds from the offering to fund the payment of capped call option transactions for the purpose of reducing potential dilution in connection with the notes.

The WilmerHale team was led by Partner Brian Johnson and included Counsel Chris Barnstable-Brown and Sarah Sellers and Associate Alicia Lee on corporate and securities matters, Partners Dino Wu and Jeannette Boot on derivatives matters, Partner John Sigel on credit matters, and Partner Julie Hogan Rodgers and Counsel Meghan Walsh on tax matters.

Read Intercept Pharmaceuticals' press release for more information. 

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
By WilmerHale
By Alan Wilson, Jonathan Wolfman
By WilmerHale
By Anna Gaudoin
By Rachel Jacobson, Nathaniel Custer, Mark Hanin
Font Size: